Barclays maintains Overweight on L'Oréal SA and raises the target price to EUR 460.00

Overview

In this L'Oréal SA company research report, Barclays highlights that beauty is one of the few consumer staples sub-sectors currently accelerating. L'Oréal SA is benefiting not only from the industry recovery but also continuing to widen its lead across regions, channels and categories. The report raises FY26e group OSG from 5.5% to 6.0%, EPS from EUR 13.63 to EUR 13.81, and the target price from EUR 450.00 to EUR 460.00, while maintaining Overweight.

Core views

The core view is that the beauty market grew by approximately 4.5% in H1 and is expected to grow by 4% to 5% for the full year, while L'Oréal SA continues to outperform by approximately 200 basis points. China's recovery is concentrated in premium channels such as Luxe and Dermatological Beauty, which better align with the company's strengths; SAPMENA-SSA is evolving from a supplementary growth source into a more important growth engine; Europe and North America are performing better than expected; and the company can fund higher A&P investment through SG&A efficiency while maintaining its margin algorithm.

Analysis framework

The report combines a top-down assessment of beauty market momentum with bottom-up revisions to regional, divisional and category forecasts, focusing on comparisons of H1 actual growth, market growth, company share performance, management's H2 guidance and the margin bridge.

Methodology notes

• Fundamental ForecastingOrganic Sales Growth Forecast

  OSG and adjusted LFL

  The report assesses adjusted like-for-like growth after removing the impact of IT phasing, and raises or lowers FY26e OSG by region and division.

• Relative RatingBarclays Equity Rating System

  Overweight

  Barclays' Overweight rating indicates that the stock is expected to outperform the equal-weighted expected total return of its industry coverage universe over a 12-month investment horizon.

• Scenario AnalysisUpside and Downside Scenarios

  Target Price Range

  The report provides an upside scenario of EUR 583.00 and a downside scenario of EUR 305.00 to reflect the valuation impact of differing growth outcomes in China, the US, Latin America, Dermatological Beauty and emerging markets.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• L'Oréal SA (OREP.PA)

  Core covered asset

  Strengths

  Global beauty leader with continued share gains across regions and categories, supported by strong brands, strong e-commerce capabilities and M&A expansion capacity.

  Weaknesses

  Valuation is relatively high, with FY26e adjusted P/E at approximately 28.5x, creating high requirements for growth delivery and resilience against a high H2 base.

  Comparison

  The report believes the company outperformed the global beauty market by approximately 200 basis points in H1, with growth quality superior to a simple industry recovery.

  Risks

  Uneven consumer confidence in China, structural pressure in the US market, rising competitive costs, and emerging markets failing to offset a slowdown in mature markets.

Key data

• RatingOverweightRating maintained.
• Target PriceEUR 460.00Raised 2% from EUR 450.00.
• Current PriceEUR 394.00Closing price on 2026-07-30.
• Potential Upside+16.8%Based on the target price and current price.
• FY26e Group OSG+6.0%Previously +5.5%.
• H1 Adjusted LFL Growth+6.5%Q1 was +6.7% and Q2 was +6.3%.
• FY26e EPSEUR 13.81Previously EUR 13.63.
• FY26e Operating Margin20.3%Full-year expectation unchanged.
• SAPMENA-SSA H1 Growth+13.8%Vietnam exceeded +50% and India reached +17%.
• FY26e OSG by DivisionProfessional +10.4%; Consumer +4.1%; Luxe +5.0%; Dermatological Beauty +9.2%Professional Products and Dermatological Beauty were upgraded, while Luxe was downgraded.

Impact & implications

If the report's assessment proves correct, the investment case for L'Oréal SA will shift from simply waiting for the beauty market to recover toward confirming its ability to sustain share gains in premium China, SAPMENA, Dermatological Beauty, Professional Products and e-commerce channels. The target price increase and FY26e forecast upgrades indicate that Barclays has greater confidence in the quality of growth and margin resilience.

Risks

• H2 faces a higher comparison base, and the market needs further confirmation that the growth algorithm is sustainable.
• China's recovery remains uneven; if consumers continue to favor local brands or lower price points, growth in Luxe and Dermatological Beauty could weaken.
• A structural slowdown in the US market could weigh on North American growth and category expansion.
• Rising competitive costs may require higher A&P investment, constraining the scope for margin improvement.
• Near-term momentum in Latin America is weaker than in SAPMENA, North America and North Asia, leaving the regional mix exposed to drag risk.

What to watch

• Whether H2 can continue to outperform the beauty market against a higher base.
• The sustainability of the recovery in China's Luxe beauty and Dermatological Beauty channels.
• Whether SAPMENA-SSA, particularly e-commerce growth in India, Vietnam and Southeast Asia, can maintain its high growth rate.
• Whether higher A&P investment continues to be supported by SG&A leverage and gross margin.
• Delivery against FY26e forecasts for Professional Products, Dermatological Beauty and Luxe.